U.S. health experts said on Wednesday that the U.S. Food and Drug Administration approved on the first vaccine against bird flu.
The new vaccine has proven effective with half of the cases that were held by the experiments, but he would not be sold commercially. Federal authorities are now buying millions of doses of this vaccine to be added to the U.S. strategic stockpile and maintained by the U.S. Centers for Prevention and Disease Control.
The head of the Office of Research vaccination Agency's U.S. Food and Drug Norman Baylor: "The risk of pandemic influenza is the most important health threats facing the United States today. This certification is the most important steps to prepare for a possible pandemic and increases our ability to protect those most vulnerable to the disease in time the current. "
The prevalence of HIV, 5 to 1 (H5N1) strain of bird flu has hit in South East Asia and Central Asia, Africa and Europe, which led to the destruction of millions of infected birds. So far, the number of victims around the world to 100 people as a result of dealing directly with live birds.
Health experts fear the virus will gain the ability to pass between humans, would result in a pandemic is expected to kill millions of people. Unlike ordinary flu, there is no acquired immunity against this type of flu in humans.
In preparation for such a pandemic, the United States has contracted to buy the equivalent of U.S. $ 100 million of new vaccination.
The experiments conducted on vaccination has proven its effectiveness with half the people who had been vaccinated in their bodies begin to produce antibodies. However, this result is modest need high doses of the vaccine up to 12 times more than the usual flu vaccination.
Acknowledged experts results did not live up to their expectations.
Says Baylor: "In better conditions I think we are we will want to get the vaccination has greater efficiency. Is vaccination effective and safe, but he needs two doses over 28 days and we will need a speed greater than that to control the epidemic. Still research ongoing to develop a vaccine, but this is What we have reached so far. "
Targeted vaccination of people between 18 and 64 years and is the most susceptible to the virus. People will be given two doses of 90 micrograms a difference a month between them.
According to Baylor, the people who are more vulnerable to disease will be identified through the government's policy may include military personnel and doctors who will enter the affected premises.
For so says Dr. Anthony Vosé who is president of the U.S. National Institute of Allergy and Infectious Diseases: "The fact that vaccination requires 90 micrograms twice a month in itself does not and will not be sufficient to answer we seek. May be a step forward but it is a small step."
The report accompanying the announcement of the discovery of vaccination, published in the New England Journal of medical findings that the "weak to moderate at best."
Baylor and confirms that the ratification of the vaccine means no need to be approved by the patient before him to give him.
"There are many new vaccines in the development stage, and this remains the option of temporary help us find a vaccine."
The new vaccine has proven effective with half of the cases that were held by the experiments, but he would not be sold commercially. Federal authorities are now buying millions of doses of this vaccine to be added to the U.S. strategic stockpile and maintained by the U.S. Centers for Prevention and Disease Control.
The head of the Office of Research vaccination Agency's U.S. Food and Drug Norman Baylor: "The risk of pandemic influenza is the most important health threats facing the United States today. This certification is the most important steps to prepare for a possible pandemic and increases our ability to protect those most vulnerable to the disease in time the current. "
The prevalence of HIV, 5 to 1 (H5N1) strain of bird flu has hit in South East Asia and Central Asia, Africa and Europe, which led to the destruction of millions of infected birds. So far, the number of victims around the world to 100 people as a result of dealing directly with live birds.
Health experts fear the virus will gain the ability to pass between humans, would result in a pandemic is expected to kill millions of people. Unlike ordinary flu, there is no acquired immunity against this type of flu in humans.
In preparation for such a pandemic, the United States has contracted to buy the equivalent of U.S. $ 100 million of new vaccination.
The experiments conducted on vaccination has proven its effectiveness with half the people who had been vaccinated in their bodies begin to produce antibodies. However, this result is modest need high doses of the vaccine up to 12 times more than the usual flu vaccination.
Acknowledged experts results did not live up to their expectations.
Says Baylor: "In better conditions I think we are we will want to get the vaccination has greater efficiency. Is vaccination effective and safe, but he needs two doses over 28 days and we will need a speed greater than that to control the epidemic. Still research ongoing to develop a vaccine, but this is What we have reached so far. "
Targeted vaccination of people between 18 and 64 years and is the most susceptible to the virus. People will be given two doses of 90 micrograms a difference a month between them.
According to Baylor, the people who are more vulnerable to disease will be identified through the government's policy may include military personnel and doctors who will enter the affected premises.
For so says Dr. Anthony Vosé who is president of the U.S. National Institute of Allergy and Infectious Diseases: "The fact that vaccination requires 90 micrograms twice a month in itself does not and will not be sufficient to answer we seek. May be a step forward but it is a small step."
The report accompanying the announcement of the discovery of vaccination, published in the New England Journal of medical findings that the "weak to moderate at best."
Baylor and confirms that the ratification of the vaccine means no need to be approved by the patient before him to give him.
"There are many new vaccines in the development stage, and this remains the option of temporary help us find a vaccine."
ليست هناك تعليقات:
إرسال تعليق